FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Summit Considering Additional Ridinilazole Trial

Summit Therapeutics says it is considering whether to hold at least one more clinical trial of its C. Diff treatment radinilazole as discussed at a me...

Human Drugs

Teva Asks Supreme Court to Hear Coreg Skinny Label Appeal

Teva asks the Supreme Court to hear its appeal of an Appeals Court decision invalidating its skinny label on a generic version of GlaxoSmithKlines Cor...

Medical Devices

Medtronic UNiD Spine Analyzer Update Cleared

FDA clears a Medtronic 510(k) for its UNiD Spine Analyzer v4.0 planning platform, which includes a new Degen Algorithm for degenerative spine procedur...

Medical Devices

FDA Clears Onkos 3D Printed Pelvic System

FDA gives 510(k) clearance to the Onkos Surgical 3D personalized pelvic reconstruction system.

Human Drugs

FDA Defers Action on BeiGene BLA

FDA defers action on a BeiGene BLA for tislelizumab to treat some squamous cell carcinoma patients.

Biologics

Inspection of Denmark Monkeypox Vaccine Facility Completed

FDA completes an inspection in Denmark of Bavarian Nordics monkeypox vaccine manufacturing plant, a step that will lead to the release of thousands of...

FDA General

House Urges Senate to Pass User Fee Reauthorization

The House Energy and Commerce Committee leadership calls on the Senate to urgently reauthorize FDAs user fee programs.

Federal Register

FDA Debars Hampton-Bey Over Misbranded Drugs

Federal Register notice: FDA issues an order debarring Kris A. Hampton-Bey II for a period of five years from importing any drug into the U.S.

Federal Register

Regulatory Review Period for Dr. Reddys Xeglyze

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Dr. Reddys Xeglyze (abametapir).

Federal Register

Hikmas Reglan Not Withdrawn Due to Safety/Efficacy: FDA

Federal Register notice: FDA determines that Hikma Pharmaceuticals Reglan (metoclopramide injection, USP) was not withdrawn due to safety or effective...